Risk of Plasmodium falciparum infection in south-west Burkina Faso: potential impact of expanding eligibility for seasonal malaria chemoprevention

Sci Rep. 2022 Jan 26;12(1):1402. doi: 10.1038/s41598-022-05056-7.

Abstract

Burkina Faso has one of the highest malaria burdens in sub-Saharan Africa despite the mass deployment of insecticide-treated nets (ITNs) and use of seasonal malaria chemoprevention (SMC) in children aged up to 5 years. Identification of risk factors for Plasmodium falciparum infection in rural Burkina Faso could help to identify and target malaria control measures. A cross-sectional survey of 1,199 children and adults was conducted during the peak malaria transmission season in the Cascades Region of south-west Burkina Faso in 2017. Logistic regression was used to identify risk factors for microscopically confirmed P. falciparum infection. A malaria transmission dynamic model was used to determine the impact on malaria cases averted of administering SMC to children aged 5-15 year old. P. falciparum prevalence was 32.8% in the study population. Children aged 5 to < 10 years old were at 3.74 times the odds (95% CI = 2.68-5.22, P < 0.001) and children aged 10 to 15 years old at 3.14 times the odds (95% CI = 1.20-8.21, P = 0.02) of P. falciparum infection compared to children aged less than 5 years old. Administration of SMC to children aged up to 10 years is predicted to avert an additional 57 malaria cases per 1000 population per year (9.4% reduction) and administration to children aged up to 15 years would avert an additional 89 malaria cases per 1000 population per year (14.6% reduction) in the Cascades Region, assuming current coverage of pyrethroid-piperonyl butoxide ITNs. Malaria infections were high in all age strata, although highest in children aged 5 to 15 years, despite roll out of core malaria control interventions. Given the burden of infection in school-age children, extension of the eligibility criteria for SMC could help reduce the burden of malaria in Burkina Faso and other countries in the region.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Amodiaquine / therapeutic use*
  • Antigens, Protozoan / blood
  • Antigens, Protozoan / immunology
  • Antimalarials / therapeutic use*
  • Burkina Faso / epidemiology
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Drug Combinations
  • Drug Therapy, Combination / methods
  • Female
  • Humans
  • Insecticide-Treated Bednets
  • Malaria, Falciparum / blood
  • Malaria, Falciparum / epidemiology*
  • Malaria, Falciparum / parasitology
  • Malaria, Falciparum / prevention & control*
  • Male
  • Middle Aged
  • Plasmodium falciparum / immunology*
  • Plasmodium falciparum / isolation & purification
  • Prevalence
  • Pyrimethamine / therapeutic use*
  • Risk Factors
  • Rural Population
  • Seasons*
  • Sulfadoxine / therapeutic use*
  • Treatment Outcome
  • Young Adult

Substances

  • Antigens, Protozoan
  • Antimalarials
  • Drug Combinations
  • Amodiaquine
  • fanasil, pyrimethamine drug combination
  • Sulfadoxine
  • Pyrimethamine